Do antibody–drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study

Introduction: Antibody–drug conjugates (ADCs) produce unparalleled efficacy in refractory neoplasms but can also lead to serious toxicities. Although ADC-related sepsis has been reported, the clinical features are not well characterized in real-world studies. Objective: The aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Shuang, Zhao, Yi-Chang, Guo, Lin, Gong, Hui, Wang, Yi-Kun, Ma, Rui, Zhang, Bi-Kui, Sheng, Yue, Sarangdhar, Mayur, Noguchi, Yoshihiro, Yan, Miao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710632/
https://www.ncbi.nlm.nih.gov/pubmed/36467034
http://dx.doi.org/10.3389/fphar.2022.967017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710632/
https://www.ncbi.nlm.nih.gov/pubmed/36467034
http://dx.doi.org/10.3389/fphar.2022.967017

Ejemplares similares